News coverage about Infinity Pharmaceuticals (NASDAQ:INFI) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.2248269428485 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

Separately, ValuEngine downgraded Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

Shares of Infinity Pharmaceuticals (INFI) traded up 5.26% during midday trading on Monday, hitting $1.20. The stock had a trading volume of 1,369,726 shares. The firm’s market cap is $60.83 million. The firm’s 50 day moving average price is $1.15 and its 200 day moving average price is $1.83. Infinity Pharmaceuticals has a 52-week low of $0.84 and a 52-week high of $3.84.

Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.12). During the same quarter in the previous year, the business posted $1.05 earnings per share. On average, equities research analysts expect that Infinity Pharmaceuticals will post ($0.92) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Infinity Pharmaceuticals (INFI) Stock Price” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/25/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-infinity-pharmaceuticals-infi-stock-price.html.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Insider Buying and Selling by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.